.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,614,506

« Back to Dashboard

Details for Patent: 5,614,506

Title: Use of hyaluronic acid and forms to prevent arterial restenosis
Abstract:For the prevention of the narrowing of the tubular walls of an animal after the tubular walls have been traumatized, the administration of a therapeutically effective non-toxic amount of hyaluronic acid and/or salts thereof and/or homologues, analogues, derivatives, complexes, esters, fragments, and subunits of hyaluronic acid to the animal to prevent narrowing of the tubular walls.
Inventor(s): Falk; Rudolf E. (Toronto, CA), Asculai; Samuel S. (Toronto, CA), Turley; Eva A. (Winnipeg, CA)
Assignee: Hyal Pharmaceutical Corporation (Mississauga, CA)
Filing Date:Aug 03, 1994
Application Number:08/285,764
Claims:1. A method of preventing the narrowing of the tubular walls of an animal after the tubular walls have been traumatized, said method comprising the administration of a therapeutically effective non-toxic amount of a form of hyaluronic acid to the animal in need thereof, the form of hyaluronic acid selected from the group consisting of hyaluronic acid, pharmaceutically acceptable salts thereof, and combinations thereof.

2. The method of claim 1, wherein the form of hyaluronic acid is sodium hyaluronate having a molecular weight less than 750,000 daltons.

3. The method of claim 1, wherein the tubular walls are arteries which have been subjected to balloon angioplasty.

4. The method of claim 2, wherein the amount of sodium hyaluronate administered is between about 10 mg/70 kg person and about 3000 mg/70 kg person.

5. A method of preventing arterial restenosis after balloon angioplasty in a human, said method comprising the administration of a therapeutically effective non-toxic amount of a form of hyaluronic acid to the human in need thereof, the form of hyaluronic acid selected from the group consisting of hyaluronic acid, pharmaceutically acceptable salts thereof, and combinations thereof.

6. The method of claim 5, wherein the form of hyaluronic acid is sodium hyaluronate having a molecular weight less than 750,000 daltons.

7. The method of claim 6, wherein the amount of the sodium hyaluronate administered is between about 10 mg/70 kg person and about 3000 mg/70 kg person.

8. The method of claim 1, 2 or 3 wherein the form of hyaluronic acid is administered intravenously.

9. The method of claim 5 or 6 wherein the form of hyaluronic acid is administered intravenously.

10. The method of claim 1, 2 or 3 further comprising administering a therapeutically effective amount of a non-steroidal anti-inflammatory drug with the form of hyaluronic acid for enhancing the effect of the form of hyaluronic acid administered in the prevention of the narrowing of the tubular walls.

11. The method of claim 5 or 6 further comprising administering an effective amount of a non-steroidal anti-inflammatory drug with the form of hyaluronic acid for enhancing the effect of the form of hyaluronic acid administered in the prevention of the arterial restenosis.

12. A method of preventing arterial restenosis after balloon angioplasty in a human, said method comprising the administration of a therapeutically effective non-toxic amount of a form of hyaluronic acid to the human in need thereof, selected from the group consisting of hyaluronic acid, pharmaceutically acceptable salts thereof and combinations thereof having a molecular weight less than 750,000 daltons.

13. The method of claim 12, wherein the amount of the form of hyaluronic acid administered is between about 10 mg/70 kg person and about 3000 mg/70 kg person.

14. The method of claim 12 further comprising administering a therapeutically effective amount of an agent selected from the group consisting of a non-steroidal anti-inflammatory drug and Vitamin C and combinations thereof with the form of hyaluronic acid for enhancing the arterial restenosis prevention effect of the administered form of hyaluronic acid.

15. The method of claim 12 further comprising administering an agent selected from the group consisting of a non-steroidal anti-inflammatory drug and Vitamin C and combinations thereof with the form of hyaluronic acid for enhancing the arterial restenosis prevention effect of the form of hyaluronic acid administered, the non-steroidal anti-inflammatory drug being selected in such amount to be effective in enhancing the arterial restenosis prevention effect of the administered form of hyaluronic acid.

16. The method of claim 14 wherein the amount of the non-steroidal anti-inflammatory drug is a dose excess of the non-steroidal anti-inflammatory drug and the amount of hyaluronic acid and salts thereof exceeds about 200 mg/70 kg person.

17. The method of claim 15 wherein the amount of the NSAID is a dose excess of the non-steroidal anti-inflammatory drug and the amount of the form of hyaluronic acid exceeds about 200 mg/70 kg person.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc